Medical Oncology

Doç. Dr. Jamshid Hamdard

Doctor and researcher Medipol Mega Üniversite Hastanesi İstanbul
Lung NeoplasmsColorectal NeoplasmsCarcinoma, Non-Small-Cell LungBreast NeoplasmsRectal NeoplasmsStomach NeoplasmsBrain NeoplasmsColonic Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Lung Neoplasms 5 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Colorectal Neoplasms 4 publications
  • Carcinoma, Non-Small-Cell Lung 3 publications
  • Breast Neoplasms 3 publications
  • Rectal Neoplasms 2 publications
  • Stomach Neoplasms 2 publications
  • Brain Neoplasms 2 publications
  • Colonic Neoplasms 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest stated by the doctor on the institution profile. Source: medipol.com.tr.

  • Meme Kanseri
  • Akciğer Kanseri
  • Kolon Kanseri
  • Rektum Kanseri
  • Baş-boyun Kanserleri
  • Cilt Kanserleri
  • Sarkomlar
  • Beyin Kanserleri
  • Testis Kanseri
  • Mide Kanseri
  • Karaciğer ve Safra yolları Kanserleri
  • Kemik Kanserleri

CV

Education and experience

From source

Dr. Jamshid Hamdard, 1984 yılında doğmuştur. Tıp eğitimini 2011 yılında İstanbul Üniversitesi İstanbul Tıp Fakültesi’nde derece ile tamamlamıştır. İç Hastalıkları uzmanlık eğitimini 2016 yılında Bezmialem Vakıf Üniversitesi’nde, Tıbbi Onkoloji yan dal uzmanlık eğitimini ise 2023 yılında Medipol Üniversitesi’nde bitirmiştir.

Kariyeri boyunca klinik araştırmalara yoğun ilgi göstermiş, özellikle meme ve akciğer kanseri üzerine çok sayıda uluslararası Faz 3 çalışmada Sorumlu Araştırmacı (PI) ve Yardımcı Araştırmacı olarak görev almıştır. Akademik bilgi birikimini 27’nin üzerinde uluslararası hakemli makale ile taçlandıran Dr. Hamdard, 2023 yılından itibaren İstanbul Medipol Üniversitesi bünyesinde akademik ve klinik çalışmalarına devam etmektedir.

Experience

  • 2016Medipol Mega Hastaneler Kompleksimedipol.com.tr
  • 2016Özel Medipol Mega Hastaneler Kompleksimedipol.com.tr

Education

  • 2023İstanbul Medipol Üniversitesi, Tıbbi Onkolojimedipol.com.tr
  • 2016İstanbul Bezmialem Vakıf Üniversitesi, İç Hastalıklarımedipol.com.tr
  • 2016Bezmialem Vakıf Üniversitesi, İç Hastalıklarımedipol.com.tr
  • 2011İstanbul Üniversitesi, İstanbul Tıp Fakültesimedipol.com.tr
  • 2011İstanbul Üniversitesi, Tıp Fakültesimedipol.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologymedipol.com.trFrom source
  • InstitutionMedipol Mega Üniversite Hastanesimedipol.com.trFrom source
  • Area of workLung NeoplasmsExtracted from 5 publications · Model version —From source
  • Publications70 publicationsOpenAlexFrom source
  • Languagesİngilizcemedipol.com.trFrom source
  • Last synchronised4 November 2026 20:21https://medipol.com.tr/doktorlarimiz/docdr-jamshid-hamdardmedipol.com.tr

Scientific work

Publications on Lung Neoplasms

70 publications

  1. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062406 PMID 41899326 Open-access full textSource: OpenAlex

  2. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy

    Pharmaceuticals, 2026

    DOI 10.3390/ph19040587 PMID 42075843 Open-access full textSource: OpenAlex

  3. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15083118 PMID 42074920 Open-access full textSource: OpenAlex

  4. Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis

    Breast Cancer Targets and Therapy, 2026

    DOI 10.2147/bctt.s647399 PMID 42936308 Open-access full textSource: OpenAlex

  5. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

    OncoImmunology, 2026

    DOI 10.1080/2162402x.2026.2738262 PMID 42788839 Open-access full textSource: OpenAlex

  6. Real-world Efficacy and Safety of Trastuzumab Deruxtecan in HER2-positive Metastatic Breast Cancer: A Multicenter Retrospective Study from Türkiye

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-1-1 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  7. Which patients with colorectal cancer develop brain metastases? A multicenter analysis of clinical and molecular predictors.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.2_suppl.218 Open-access full textSource: OpenAlex

  8. Unveiling the Uncommon: A Comprehensive Review and Case Report on Targeting Rare MET Fusions in NSCLC

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-7-10 Open-access full textSource: OpenAlex

  9. The Impact of the Systemic Immune-inflammation Index and the Systemic Inflammatory Response Index on Progression-free Survival and Overall Survival in Second-line Immunotherapy for Metastatic Non-small Cell Lung Cancer

    Bagcilar Medical Bulletin, 2026

    DOI 10.4274/bmb.galenos.2026.70299 Open-access full textSource: OpenAlex

  10. Investigation of Predictive and Prognostic Factors in Metastatic Renal Cell Carcinoma (mRCC) Patients Receiving First-line Treatment: A Retrospective Single-center Experience

    Bagcilar Medical Bulletin, 2026

    DOI 10.4274/bmb.galenos.2026.78942 Open-access full textSource: OpenAlex

View all 70 publications